45
Otsuka
4578.T·TSETokyo JPFounded 196433,000 employees
Large CappharmaPublicCNSNephrologyOncology
Platform: Neuropsych
Market Cap
$20B
All Drugs
6
Clinical Trials
12
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (4578.T)
Loading 4578.T stock data...
Drug Pipeline (6 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Doxafotisoran | 457-6977 | NDA/BLA | 2 | TIM-3 | PompeBCC | ||
| Rimainavolisib | 457-6387 | Phase 3 | 4 | TYK2 | GAMelanoma | ||
| Rilutenlimab | 457-2356 | Phase 2 | 2 | GIP-R | SMAHemophilia A | ||
| Capitapinarof | 457-8367 | Preclinical | 1 | RET | Endometrial CaSchizophrenia | ||
| Rilulucimab | 457-9053 | Phase 2 | 2 | PSMA | LGS | ||
| Gelibrutinib | 457-8835 | Phase 1 | 1 | PCSK9 | FL |
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Otsuka trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (10)